Clinical Trial Update: Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating nanobody-based Biepitope CAR-T cells targeting BCMA for relapsed/refractory multiple myeloma. The study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Nanobody-based Biepitope BCMA-targeted CAR-T cells (BCMA-targeted CAR-T cell therapy using nanobody-based biepitopes)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING